

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/041388

International filing date: 09 December 2004 (09.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/529,449  
Filing date: 11 December 2003 (11.12.2003)

Date of receipt at the International Bureau: 31 March 2005 (31.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1298921

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*March 21, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/529,449**

**FILING DATE: *December 11, 2003***

**RELATED PCT APPLICATION NUMBER: *PCT/US04/41388***



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

17157 U.S. PTO  
121103

PTO/SB/16 (08-03)  
Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. ET 735 975 205 US

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Eric R. Gleb P.		Kandel Shumyatsky		New York, NY Tenafly, NJ	
Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
GRP RECEPTOR-RELATED METHODS FOR TREATING AND PREVENTING FEAR-RELATED DISORDERS					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number: <div style="border: 1px solid black; width: 280px; height: 30px; display: inline-block;"></div>					
OR					
<input checked="" type="checkbox"/> Firm or Individual Name John P. White					
Address Cooper & Dunham LLP					
Address 1185 Avenue of the Americas					
City New York		State NY	Zip 10036		
Country U.S.A.		Telephone (212)-278-0400	Fax (212)-391-0525		
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages <u>52 pgs.</u>		<input type="checkbox"/> CD(s), Number _____			
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets <u>6</u>		<input checked="" type="checkbox"/> Other (specify) <u>Claims 4 pgs; Abstract 1pg</u>			
<input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE Amount (\$)	
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees.				<div style="border: 1px solid black; width: 120px; height: 50px; text-align: center; line-height: 50px;">160.00</div>	
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>03-3125</u>					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

15385 U.S. PTO  
60/529449  
121103

Respectfully submitted,

[Page 1 of 2]

Date 12/11/03

SIGNATURE

REGISTRATION NO. 37,399

TYPED or PRINTED NAME Alan J. Morrison

(if appropriate)

Docket Number: 70442-PRO/JPW/AJM/NS

TELEPHONE 212-278-0400

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**PROVISIONAL APPLICATION COVER SHEET**  
**Additional Page**

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number 70442-PRO/JPW/AJM/NS

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any] )	Family or Surname	Residence (City and either State or Foreign Country)
Vadim Y. Gael	Bolshakov Malleret	Belmont, MA New York, NY

[Page 2 of 2]

Number 1 of 1

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Eric Kandel et al.  
U.S. Serial No.: Not Yet Known  
Filed : Herewith  
For : GRP RECEPTOR-RELATED METHODS FOR TREATING  
AND PREVENTING FEAR-RELATED DISORDERS

1185 Avenue of the Americas  
New York, New York 10036  
December 11, 2003

Mail Stop Provisional Patent  
Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


SIR:

EXPRESS MAIL CERTIFICATE OF MAILING  
FOR THE ABOVE-IDENTIFIED APPLICATION


"Express Mail" mailing label number: ET 735 975 205 US

Date of Deposit: December 11, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. \$1.10 on the date indicated above and is addressed to the Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Printed Name: Teron Breland

Respectfully submitted,

  
John P. White  
Registration No. 28,678  
Alan J. Morrison  
Registration No. 37,399  
Attorneys for Applicants  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
Tel. No. (212) 278-0400

**GRP RECEPTOR-RELATED METHODS FOR TREATING AND  
PREVENTING FEAR-RELATED DISORDERS**

The invention disclosed herein was made with U.S. government support under grant number MH50733 from  
5 the National Institute of Mental Health and with support under grant numbers NS44185 and DA15098 from the National Institutes of Health. Accordingly, the U.S. government has certain rights in this invention.

Throughout this application, various publications are  
10 referenced by author and date. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these references in their entireties are hereby incorporated by reference into this  
15 application to describe more fully the art to which this invention pertains.

**Background of the Invention**

*Physiology of Fear*

Fear is a basic, evolutionally conserved, emotion  
20 which triggers a set of defensive mechanisms for adapting to threatening events that is essential for survival. A key component of the neural circuitry of fear, both innate and learned, in humans and in simpler vertebrate experimental animals is the  
25 amygdala, a well-defined subcortical nuclear group (Davis and Whalen, 2001; LeDoux, 2000).

The memory of learned fear can be assessed quantitatively using a Pavlovian fear-conditioning paradigm (Fanselow and LeDoux, 1999; Kapp et al.,  
30 1992). During fear conditioning, an initially neutral conditioned stimulus (CS) acquires biological

significance by becoming associated, following a few pairing trials, with an aversive unconditioned stimulus (US). After learning this association, the animal responds to the previously neutral CS with a set of defensive behavioral response, which includes freezing, increased heart rate, and startle. The CS can be unimodal, involving only a single cue or modality such as a tone, light, smell, or touch. Alternatively, it can be multimodal, involving several sensory modalities such as a context. Unimodal (cued) fear conditioning requires the amygdala but not the hippocampus. By contrast, multimodal (contextual) fear conditioning depends on both the hippocampus and the amygdala.

The lateral nucleus is the input region within the amygdala, where the association of learned information about CS and US occurs during auditory fear conditioning. The sensory information that mediates the CS - the auditory tone - reaches the lateral nucleus by way of two neural pathways, both of which are essential for learned fear (Romanski and LeDoux, 1992). One pathway, the direct thalamo-amygdala pathway, originates in the medial geniculate nucleus (MGm) and in the posterior intralaminar nucleus (PIN) of the thalamus. The second pathway, the indirect cortico-amygdala pathway, extends from the auditory thalamus to the auditory cortex (TE3 area) and includes a further projection that relays the processed auditory information from the cortex to the lateral amygdala. After these two inputs are processed in the lateral nucleus, the signal is distributed to other amygdaloid nuclei (Pitkanen et al. 1997), including the central nucleus of the

amygdala (CeA), which projects in turn to areas in the brainstem that control autonomic (heart rate) and somatic motor centers (freezing) involved in the expression of fear.

5 Anatomical tracing and lesion studies first demonstrated the importance of the lateral nucleus for fear conditioning. Subsequent physiological experiments showed that learning produces prolonged synaptic modification in both of the inputs to the  
10 lateral nucleus: the thalamo-amygdala pathway (McKernan and Shinnick-Gallagher, 1997; Rogan et al., 1997) and the cortico-amygdala pathway (Tsvetkov et al., 2002). These synaptic modifications, which accompany behavioral learned fear, are  
15 mechanistically similar to LTP induced artificially by electrical stimulation in tissue slices of the amygdala. By providing a direct causal link between slice LTP and memory storage, these studies establish the amygdala as perhaps the simplest and the best  
20 model system in the mammalian brain for analyzing the cellular and molecular mechanisms of memory storage.

In contrast to the detailed cellular physiological information that is becoming available, the molecular machinery that underlies synaptic plasticity in  
25 amygdala-dependent learned fear is largely unknown.

#### *Neuropeptides and Anxiolytics*

A number of neuropeptides are believed to be involved in the pathophysiology of anxiety, including, for example, cholecystokinin (CCK), corticotropin-releasing factor and neuropeptide Y. Gastrin  
30 releasing peptide (GRP) is known as a potent satiety



agent (see Merali, Z. et al. 1994). GRP antagonists are also known in the field of cancer research for their use in inhibiting tumor growth.

Gastrin releasing peptide (GRP) and neuromedin B (NMB) are mammalian homologs of bombesin, a 14 amino acid peptide hormone first isolated from the skin of the frog, *Bombina bombina*. Three bombesin-like peptide receptors are known: gastrin releasing peptide receptor (GRPR; BB2), neuromedin B receptor (NMBR; BB1) and bombesin receptor subtype-3 (BRS-3; BB3). All are G-protein coupled receptors. Gastrin releasing peptide receptor is known in the art by the acronyms GRPR and BB2 (for bombesin receptor subtype 2). Potent and selective peptide agonists of the gastrin releasing peptide receptor (BB2) are known. For example, Darker, J.G. et al. (2001) and Casibang, M. and Moody, T.W. (2000) describe such agonists. Bombesin agonists are also known, for example Condamine E. et al. (1998).

More generally, assays for agonists or antagonists of G-protein coupled receptors are known in the art. See, for example, Fitzgerald, L.R., (1999). Similarly, one of skill in the art can determine the expression of GRPR in a cell or tissue sample using routine methods (see Kusui et al. 1995).

Gamma-aminobutyric acid (GABA), along with norepinephrine and serotonin, is known to be important in the regulation of anxiety. GABA is the major inhibitory neurotransmitter in the mammalian central nervous system (CNS) and is utilized for intercellular communication by approximately one-third of all synapses in the CNS. There are two

classes of GABA receptors, A and B. The GABA-A receptor is comprised of five peptide subunits (alpha, beta, gamma, delta, and rho) which form a chloride-permeable ion channel coupled to a G-protein. Each of the five subunits may have multiple isoforms. For example, there are six alpha, four beta, three gamma, one delta, and two rho subunits known presently.

Anxiolytics are compounds that relieve anxiety. Known anxiolytic compounds include GABA-A agonists such as the benzodiazepines, which are the prototypic anti-anxiety compounds. Benzodiazepines interact with binding sites which are largely defined by the alpha subunit of the GABA-A receptor complex. In older literature, the GABA-A receptor complex was referred to as the "benzodiazepine receptor" or BZR. More than two-dozen benzodiazepines are in clinical use in the United States. Among these are Alprazolam (Xanax), chlordiazepoxide (Librium), and diazepam (Valium). Other examples of anxiolytic compounds are neurohormones such as 3-alpha, 5-alpha-pregnanolone (THPROG) and muscimol.

Animal tests for anxiolytic activity are known in the art. For example, one test involves pairing a reward for which the animal must perform some behavior, such as lever pressing, with an aversive stimulus, such as mild electric shock. Agents that increase the rate of responses punished with the shock tend to be anxiolytic in humans (see basic Neurochemistry, 6th ed. Siegel et al. editors). Another indicator of anxiolytic activity is a compound's binding affinity for the GABA-A receptor.

### Summary of the Invention

This invention provides a method for treating a subject afflicted with a fear-related disorder comprising administering to the subject a  
5 therapeutically effective amount of a gastrin-releasing peptide receptor agonist.

This invention further provides a method for inhibiting in a subject the onset of a fear-related disorder resulting from exposure to a traumatic  
10 experience comprising administering a prophylactically effective amount of a gastrin-releasing peptide receptor agonist to the subject prior to and/or following the traumatic experience.

This invention further provides an article of  
15 manufacture comprising (a) a packaging material having therein a gastrin-releasing peptide receptor agonist, and (b) a label indicating a use for the agonist in treating, and/or inhibiting the onset of, a fear-related disorder in a subject.

20 This invention further provides a nucleic acid comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-releasing peptide.

25

This invention further provides a transgenic animal whose somatic cells have stably integrated therein a nucleic acid comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either  
30 at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-

releasing peptide, and wherein the polypeptide is specifically expressed in the animal's amygdala.

Finally, this invention provides a method for  
5 producing a transgenic animal whose amygdaloid cells specifically express an exogenous polypeptide, which method comprises producing a transgenic animal by introducing into an oocyte an exogenous DNA so that the exogenous DNA is stably integrated into the  
10 oocyte, and permitting the resulting oocyte to mature into a viable animal, wherein (a) the animal's somatic cells have the exogenous DNA stably integrated therein, (b) the exogenous DNA comprises a gastrin-releasing peptide gene, wherein the gene has  
15 inserted into it, either at its start or stop codon, an exogenous polypeptide-encoding sequence, and the exogenous polypeptide is not gastrin-releasing peptide, and (c) the exogenous polypeptide is specifically expressed in the animal's amygdala.

20

## **Brief Description of the Figures**

Figure 1: The Grp Gene is Specifically Expressed in the Lateral Nucleus/AB of the Amygdala and in the Cued and Contextual CS Pathways to the Amygdala.

5 Schematic of a mouse brain showing the location of coronal sections C1 and C2 and RNA in situ hybridization showing expression of the Grp gene therein. Below is a diagram depicting the major areas that send auditory and contextual information to the

10 amygdala obtained from tract-tracing studies.

Figure 2: GRP Receptors Are Functionally Expressed in Interneurons of the Lateral Nucleus of the Amygdala.

(A1) Bath application of GRP (200 nM) increased frequency of sIPSCs in a pyramidal cell from a

15 control mouse. The effect was blocked by 3 $\mu$ M bombesin antagonist (n = 6), thus suggesting that the GRP-induced enhancement of GABAergic tonic inhibition was specifically linked to the activation of the GRP receptors.

20 (A2) Effect of GRP on the frequency of sIPSCs is TTX-sensitive, and thus is dependent on action potential firing in interneurons.

(A3) GRP failed to increase the frequency of the picrotoxin-sensitive sIPSCs in GRPR knockout mice.

25 (B1) Representative sIPSCs recorded in a pyramidal cell from a control mouse at a holding potential of -70 mV under baseline conditions (left), during GRP application (center), and after the GRPR antagonist was added (right).

(B2) Representative sIPSCs recorded in a pyramidal neuron from GRPR knockout mouse under baseline conditions (left), during GRP application (center), and after picrotoxin was added (right).

- 5 (C) Cumulative amplitude histograms of sIPSCs recorded under baseline conditions (filled symbols) and after GRP was applied (open symbols) in slices from control (left) and GRPR knockout mice.

Figure 3: Pairing-Induced LTP is Enhanced in GRPR  
10 Knockout Mice. Pairing-induced LTP of whole-cell EPSCs recorded in the lateral amygdala in wild-type mice under control conditions (open symbols) and in the presence of the bombesin antagonist (3  $\mu$ M, filled symbols).

- 15 (A) A schematic representation of a brain slice containing the amygdala that shows position of the recording and stimulation pipettes.

(B) LTP of whole-cell EPSCs recorded in the lateral amygdala neuron in response to the cortical input  
20 stimulation in slices from control (open symbols) or GRPR knockout (filled symbols) mice. For induction of LTP, the lateral amygdala neuron was held at +30 mV, and 80 presynaptic stimuli were delivered at 2 Hz to the external capsule fibers (arrow).

- 25 (C) Current-voltage plot of the GABA<sub>A</sub> receptor IPSCs at holding potentials of -110 mV to -10 mV. Reversal potential of the IPSC mediated by the GABA<sub>A</sub> receptors was -71 mV. Synaptic currents were recorded in the presence of the AMPA receptor antagonist CNQX (20  $\mu$ M)  
30 and NMDA receptor antagonist D-APV (50  $\mu$ M). Inset shows GABA<sub>A</sub> receptor IPSCs recorded at holding

potentials of -110 mV to -10 mV. Traces are averages of 10 IPSCs recorded at each holding potential.

(D) Pairing-induced LTP of whole-cell EPSCs recorded in the lateral amygdala in wild-type mice under control conditions (open symbols) and in the presence of the bombesin antagonist (3 uM, filled symbols).

Figure 4: GRPR-Deficient Mice Have Enhanced and Resistant Long-Term But Not Short-Term Amygdala-Dependent Fear Memory

(A1) Contextual fear conditioning. Significant difference in freezing responses between GRPR knockout mice (n = 9, solid bars) and wild-type (n = 9, open bars) mice was found at 24 hr, 2, 7, and 15 weeks after training.

(A2) Cued fear conditioning. In response to the tone (CS), both groups showed an increase in freezing. However, this increase was significantly higher in GRPR knockout animals, although no difference was found between groups in the level of freezing before the onset of the tone (pre-CS).

(B1) Contextual and (B2) cued-fear conditioning assessed 30 min or 4 hr after training was normal in GRPR knockout mice.

(C1-4) Water Maze. (wild-type, n = 9; knockout, n = 9). In this hippocampus-dependent memory task, both groups of mice showed a similar rate of learning as demonstrated by their equivalent latency (C1) to reach the platform, whether it is during the visible (Day 1 and 2) or hidden platform version of the task (Day 3-6). They displayed the same swimming speed

(C2), and thigmotaxis (% of time spent at the periphery; C3). They also showed equivalent performance in the probe trial (% of time spent in the different quadrant areas; C4), which assessed the retention of spatially acquired information necessary to perform this task. GRPR knockout mice are no more sensitive or stressed than wild-type mice (D and E).

(D) Pain sensitivity thresholds. The intensity of shock required to elicit three reactions, movement (movt), vocalization (vocal), and jump, was assessed and data are presented as the mean  $\pm$  SEM. No difference was found between groups (wild-type, n = 10; knockout, n = 8).

(E) Elevated plus maze assessing basal anxiety. No difference was found between GRPR (n = 18) and wild-type mice (n = 16) in the total number of entries, as in the number of entries in the closed or open arms.

Figure 5: A Model for GRP-Dependent Negative Feedback to Principal Neurons in the Amygdala in Wild-Type and GRPR Knockout Mice.



## Detailed Description of the Invention

### Definitions

As used herein, "administering" shall mean delivering in a manner which is effected or performed using any of the various methods and delivery systems known to those skilled in the art. Administering can be performed, for example, intravenously, orally, via implant, transmucosally, transdermally, intramuscularly, or subcutaneously. "Administering" can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.

As used herein, "agent" shall include, without limitation, an organic compound, a nucleic acid, a polypeptide, a lipid, and a carbohydrate. Agents include, for example, agents which are known with respect to structure and/or function, and those which are not known with respect to structure or function.

As used herein, "agonist of gastrin-releasing peptide receptor", or its synonymous term "gastrin-releasing peptide receptor agonist", shall mean an agent that, when bound to gastrin-releasing peptide receptor, stimulates a biological response like the biological response stimulated when gastrin-releasing peptide is bound to gastrin-releasing peptide receptor. For example, an agonist of the GRP receptor can enhance inhibitory function of interneurons containing GRPR, which leads to increased GABA release by interneurons. The magnitude of the biological response stimulated by a gastrin-releasing peptide receptor agonist can be the same as, greater than or less than the biological response stimulated by

gastrin-releasing peptide. Methods of identifying gastrin-releasing peptide receptor agonists are well-known in the art. (see e.g. U.S. Patent No. 5,741,651, at column 2, line 38). Gastrin-releasing peptide agonists include, without limitation, bombesin, gastrin-releasing peptide fragments, and mutants of gastrin-releasing peptide and its fragments (e.g. point mutants), and analogs of gastrin-releasing peptide and its fragments (e.g. gastrin-releasing peptide and its fragments wherein one or more amino acid residues are substituted with an amino acid derivative). Amino acid derivatives are well known in the art (see, e.g. U.S. Patent No. 6,552,061). Additional agonists are described in Darker et al. 2001, and include, for example, GRP (aminoacids 19-27; available from Bachem, USA); [D-Phe<sup>6</sup>, βAla<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]Bn(6-14) amide; [Glp<sup>7</sup>, βAla<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]Bn(7-14) amide; [βAla<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]Bn(9-14) amide; and [βAla<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]Bn(10-14) amide. These agonists have very high affinity to GRPR, but very little or no affinity to other receptors from the mammalian bombesin family.

As used herein, a "fear-related disorder" shall mean any disorder induced by or resulting from an event that causes apprehension or alarm in the afflicted subject.

As used herein, "gastrin-releasing peptide" is a naturally occurring peptide that elicits gastrin release and regulates gastric acid secretion and motor function in a subject. Gastrin-releasing peptide can be from a human or any other subject. The terms "gastrin releasing peptide", "gastrin-

releasing peptide" and "GRP" are synonymous.

As used herein, with respect to claims for transgenic animals and methods of making same, "gastrin-releasing peptide gene", or "GRP gene", shall mean a  
5 naturally occurring GRP-encoding DNA sequence (including introns), contiguous at its 5' end with at least about 30 kb of DNA sequence which is naturally contiguous with the 5' end of the GRP-encoding DNA  
10 30kb of the DNA sequence which is naturally contiguous with the 3' end of the GRP-encoding DNA sequence.

As used herein, "inhibiting" the onset of a disorder shall mean either lessening the likelihood of the  
15 disorder's onset, or preventing the onset of the disorder entirely. In the preferred embodiment, inhibiting the onset of a disorder means preventing its onset entirely.

As used herein, "nucleic acid" shall mean any nucleic  
20 acid molecule, including, without limitation, DNA, RNA and hybrids thereof. The nucleic acid bases that form nucleic acid molecules can be the bases A, C, G, T and U, as well as derivatives thereof. Derivatives of these bases are well known in the art, and are  
25 exemplified in PCR Systems, Reagents and Consumables (Perkin Elmer Catalogue 1996-1997, Roche Molecular Systems, Inc., Branchburg, New Jersey, USA).

As used herein, "protein" and "polypeptide" are used  
equivalently, and each shall mean a polymer of amino  
30 acid residues. The amino acid residues can be naturally occurring or chemical analogues thereof.

Polypeptides and proteins can also include modifications such as glycosylation, lipid attachment, sulfation, hydroxylation, and ADP-ribosylation.

- 5 As used herein, "subject" shall mean a human or any animal, such as a non-human primate, mouse, rat, guinea pig, dog, cat, or rabbit.

As used herein, a "traumatic experience" includes, without limitation, military combat, physical  
10 assault, witnessing a physical assault, and experiencing a natural disaster, animal attack, or an emergency situation.

As used herein, "treating" a subject afflicted with a disorder shall mean either lessening the severity of  
15 the disorder, or eliminating the disorder entirely.

#### Embodiments of the Invention

The present invention is based upon the discovery that gastrin-releasing peptide (GRP) is also an important regulator of certain types of anxiety,  
20 namely those involving amygdala-dependent learned fear.

Specifically, this invention provides a method for treating a subject afflicted with a fear-related disorder comprising administering to the subject a  
25 therapeutically effective amount of a gastrin-releasing peptide receptor agonist.

In one embodiment of the instant therapeutic method, the subject is human. Fear-related disorders treated include, for example, phobia, chronic anxiety, panic

attack, post-traumatic stress disorder, and autism.

This invention further provides a method for inhibiting in a subject the onset of a fear-related disorder resulting from exposure to a traumatic  
5 experience comprising administering a prophylactically effective amount of a gastrin-releasing peptide receptor agonist to the subject prior to and/or following the traumatic experience.

In one embodiment of the instant prophylactic method,  
10 the subject is human. An agonist would be administered, for example, prior to a foreseeable traumatic experience such as military combat. In one embodiment, the agonist would be administered between 1 and 20 days, or 5 and 10 days prior to the  
15 traumatic experience. In a further embodiment, the agonist would be administered between 1 and 48 hours, or 12 and 24 hours prior to the traumatic experience. In a further embodiment, the agonist would be administered between 60 and 120 minutes, or 1 and 30  
20 minutes prior to the traumatic experience.

An agonist would also be administered, for example, following a traumatic experience such as a physical assault. In one embodiment, the agonist would be administered between 1 and 20 days, or 5 and 10 days,  
25 following the traumatic experience. In a further embodiment, the agonist would be administered between 1 and 48 hours, or 12 and 24 hours following the traumatic experience. In a further embodiment, the agonist would be administered between 60 and 120  
30 minutes, or 1 and 30 minutes following the traumatic experience.

Determining a therapeutically or prophylactically effective amount of the agonists used in the instant invention can be done based on animal data using routine computational methods. In one embodiment, 5 the therapeutically or prophylactically effective amount contains between about 0.1 mg and about 1 g of agonist. In another embodiment, the effective amount contains between about 1 mg and about 100 mg of agonist. In a further embodiment, the effective 10 amount contains between about 10 mg and about 50 mg of agonist.

This invention further provides an article of manufacture comprising (a) a packaging material having therein a gastrin-releasing peptide receptor 15 agonist, and (b) a label indicating a use for the agonist in treating, and/or inhibiting the onset of, a fear-related disorder in a subject.

This invention further provides a nucleic acid 20 comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-releasing peptide. For mice, the GRP gene is located on chromosome 18. 25 The gene contains 3 exons, a transcript length of 862 bp, and a translation length of 146 residues. All information regarding the GRP gene (coded by Q8R1I2 (SPTREMBL ID)) is contained at Ensemble site at [http://www.ensembl.org/Mus\\_musculus/geneview?gene=ENSMUSGO](http://www.ensembl.org/Mus_musculus/geneview?gene=ENSMUSGO) 30 0000024517.

This invention further provides a transgenic animal whose somatic cells have stably integrated therein a

nucleic acid comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-releasing peptide, and wherein the polypeptide is specifically expressed in the animal's amygdala. In one embodiment of the instant method, the transgenic animal is a mouse. Methods for making transgenic animals by introducing foreign DNA into embryonic cells and transplanting resulting cells into the uterus of an animal for development to term are well known in the art. (see e.g. U.S. Patent No. 4,870,009). The foreign DNA can be introduced either by gene targeting "knock-in" technology or BAC transgenic technology (using DNA recombination in bacteria).

Finally, this invention provides a method for producing a transgenic animal whose amygdaloid cells specifically express an exogenous polypeptide, which method comprises producing a transgenic animal by introducing into an oocyte an exogenous DNA so that the exogenous DNA is stably integrated into the oocyte, and permitting the resulting oocyte to mature into a viable animal, wherein (a) the animal's somatic cells have the exogenous DNA stably integrated therein, (b) the exogenous DNA comprises a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, an exogenous polypeptide-encoding sequence, and the exogenous polypeptide is not gastrin-releasing peptide, and (c) the exogenous polypeptide is specifically expressed in the animal's amygdala.

This invention is illustrated in the Experimental Details section which follows. This section is set forth to aid in an understanding of the invention but is not intended to, and should not be construed to, limit in any way the invention as set forth in the  
5 claims which follow thereafter.



## Experimental Details

### Synopsis

The present invention identifies two genes highly enriched in the lateral nucleus of the amygdala: the  
5 gastrin-releasing peptide (GRP) and oncoprotein 18 (Op18)/Stathmin. We focused on GRP because it is presumably released as a cotransmitter with glutamate in pyramidal cells of the lateral nucleus and its receptor (GRPR) has been pinpointed as a candidate in  
10 autism. This invention demonstrates that, when released by activity, GRP acts on and excites inhibitory interneurons by activating GRPR on their cell surface. Activation of GRPR in these interneurons in turn leads to an increase in the  
15 level of tonic GABAergic inhibition in the principal neurons. This invention further demonstrates that in amygdala slices from GRPR knockout mice, the tonic inhibition is markedly reduced and LTP is enhanced. Consistent with this finding, these mice have  
20 enhanced and prolonged long-term memory for fear to both auditory and contextual cues, suggesting that the GRP signaling pathways serves as an inhibitory feedback constraint on learned fear.

### Methods

#### 25       *Animals*

GRPR knockout mice were described before and were found grossly normal (Hampton et al., 1998). Mice used for the study were back-crossed to N10 or more to C57BL/6J strain.

### *Differential Screening*

Amygdala cells were acutely dissociated as described (Yu and Shin-nick-Gallagher, 1997). Cells morphologically resembling pyramidal neurons were identified under low magnification Nikon microscope and individually transferred to PCR tubes containing lysis buffer. cDNA libraries were synthesized as described (Dulac and Axel, 1995). Five thousand clones were differentially screened with the amygdala and CA1 single cell cDNA probes. Amygdala probes for the differential screening were enriched by two rounds of subtraction of representational difference analysis (Hubank and Schatz, 1994) against the CA1 cDNA.

### *In Situ Hybridization/Immunohistochemistry*

Coronal sections from fresh-frozen mouse brains were cut 20 microns thick and hybridized according to the published protocol with modifications (Schaeren-Wiemers and Gerfin-Moser, 1993). For dual fluorescent in situ hybridization and immunohistochemistry, digoxigenin-labeled RNA was first detected using tyramide-based TSA Direct Fluorescein Kit (Perkin Elmer). Then, sections were incubated with rabbit antibody recognizing glutamic acid decarboxylase (Chemicon) and detected using Cy3-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch).

### *Electrophysiology*

Amygdala slices (250-300 um) were prepared from 3-5 week old control and GRPR knockout mice (littermates) with a vibratome. Slices were continuously superfused in solution containing (in mM): 119 NaCl, 2.5 KCl,

2.5  $\text{CaCl}_2$ , 1.0  $\text{MgSO}_4$ , 1.25  $\text{NaH}_2\text{PO}_4$ , 26.0  $\text{NaHCO}_3$ , 10 glucose, and equilibrated with 95%  $\text{O}_2$  and 5%  $\text{CO}_2$  [pH 7.3-7.4] at room temperature. Whole-cell recordings of evoked compound EPSCs or spontaneous GABA-mediated IPSCs were obtained from pyramidal cells in the lateral amygdala under visual guidance (DIG/ infrared optics) with an EPC-9 amplifier and Pulse v8.09 software (HEKA Elektronik). Compound EPSCs were evoked by stimulation of the fibers in the external capsule at 0.05 Hz with a concentric stimulating electrode consisting of a patch pipette (10  $\mu\text{m}$  tip diameter) that was coated with silver paint (Bolshakov et al., 1997). The two leads of the stimulus isolation unit (ISO-Flex, Master-8 stimulator, AMPI, Jerusalem, Israel) were connected to the inside of the pipette and the external silver coat. The stimulating pipette was positioned to activate the cortical input to the lateral amygdala. To elicit the evoked  $\text{GABA}_A$  IPSCs in the presence of CNQX (20  $\mu\text{M}$ ) and D-APV (50  $\mu\text{M}$ ) in the bath, the stimulation electrode was placed within the lateral nucleus of the amygdala. The patch electrodes (3-5 M $\Omega$  resistance) contained (in mM): 120 KCl, 5 NaCl, 1  $\text{MgCl}_2$ , 0.2 EGTA, 10 HEPES, 2 MgATP, and 0.1 NaGTP (adjusted to pH 7.2 with KOH). In LTP experiments, 120 mM K-gluconate was used instead of KCl. To examine the voltage dependence of the evoked  $\text{GABA}_A$  receptor IPSCs, cesium was substituted for potassium in the pipette solution. Series resistance was monitored throughout experiment and was in a range of 10-20 M $\Omega$ . Currents were filtered at 1 kHz and digitized at 5 kHz. The holding potential was -70 mV. In all LTP experiments, the stimulus intensity was adjusted to produce synaptic responses with an

amplitude which constitutes ~20%-25% of maximum amplitude EPSC. Since we controlled for the size of the baseline EPSC, the induction conditions were identical for both LTP groups (control and knockout mice). The EPSC amplitudes were measured as the difference between the mean current during a prestimulus baseline and the mean current over a 2 ms-window at the peak of the response. For induction of LTP, 80 presynaptic stimuli were delivered at 2 Hz to the external capsule fibers while the lateral nucleus of the amygdala neuron was held at +30 mV for the duration of the LTP-inducing presynaptic stimulation. Summary LTP graphs were constructed by normalizing data in 60 s epochs to the mean value of the baseline EPSC.

The spontaneous IPSCs were recorded on videotape for off line analysis in the presence of 20  $\mu$ M CNQX. Data were analyzed with the Mini Analysis Program v5.2.4 (Synaptosoft Inc., Decatur, GA; Bolshakov et al., 2000).

### *Behavior*

For all behavioral tasks, mutant and control littermates (males, 3 months old) were used. Statistical analyses used ANOVAs with genotype as the between subject factor, and session (fear conditioning experiment), day, area (quadrant or platform in the Morris water maze), or zone (elevated plus maze and light-dark box) as within subject factors. Mean  $\pm$  SEM are presented. The experimenter was blind to the genotype in all studies.

Fear conditioning experiments were done as described

(Bourt-chouladze et al., 1998). On the training day, the mouse was placed in the conditioning chamber (Med Associates) for 2 min before the onset of CS, a tone, which lasted for 30 s at 2800 Hz, 85 dB. The last 2 s of the CS was paired with US, 0.7 mA of continuous foot shock. After an additional 30 s in the chamber, the mouse was returned to its home cage. Conditioning was assessed for 3 consecutive min in the chamber in which the mice were trained by scoring freezing behavior, which was defined as the complete lack of movement, in intervals of 5 s. Mice (wild-type, n = 9; knockout, n = 9) were tested immediately after training and at 24 hr, 2, 7, and 15 weeks after training. For each time point, testing occurred first in the context in which mice were trained (contextual fear conditioning). Three hours after each contextual testing session, mice were placed in a novel environment (cued fear conditioning) in which the tone (120 s) that has been presented during training was given after a 1 min habituation period (pre-CS).

#### *Pain Sensitivity Tests*

Response to foot shocks was assessed with naive mice (wild-type, n = 10; knockout, n = 8) as described (Harrel, 2001). The intensity of shock required to elicit running, vocalization, and a jump was determined for each mouse by delivering a 1 s shock every 30 s starting at 0.08 mA and increasing the shock 0.02 mA each time. Testing was stopped after all behaviors had been noted.

#### *Anxiety Tests*

We performed two different tasks to assess basal

anxiety level in naive mice.

#### *Elevated Plus Maze*

The elevated plus maze consisted of a center platform and four arms placed 50 cm above the floor (Ramboz et al., 1998). Two arms were enclosed within walls and the other two (open) had low rims. Naive mice (wild-type, n = 18; knockout, n = 16) were placed in the center and their behavior was recorded for 5 min with a camera located above the maze. Time spent (in seconds, s) and entries in the different compartments (closed and open arms, center) were assessed.

#### *Dark-Light Box*

For the dark-light box test, mice (wild-type, n = 10; knockout, n = 9) were placed in the dark compartment (head facing the wall) and observed for 5 min (Johansson et al., 2001). Time spent in and entries into the lit compartment were recorded.

#### *Water Maze*

The task was performed as previously described (Malleret et al., 1999) with two training phases: 2 days with a visible platform followed by 4 days (spatial phase) with a hidden platform in the training quadrant (wild-type, n = 9; knockout, n = 9). For each phase, four trials, 120 s maximum and 15 min ITI (intertrial interval) were given daily. Probe trials (60 s), during which the platform was removed, were performed to assess retention of the previously acquired information.

## Results

### *Isolation of Genes Specifically Expressed in the Lateral Nucleus of the Amygdala*

As an initial step in characterizing the molecular mechanisms involved in learned fear, we searched for genes enriched in the amygdala and, in particular, in the lateral nucleus. To this end, we focused on pyramidal projection neurons because these cells form the majority of the constituent neurons in the cortex-like nuclei of the amygdala to which the lateral nucleus belongs and they transmit the CS and US information during fear learning. We isolated neurons using acute dissociation, which preserves their processes and allows cell identification based on neuronal morphology under the microscope (Yu and Shinnick-Gallagher, 1997). Similarly, pyramidal neurons were isolated from the anterior dorsal CA1 subregion of the hippocampus, which was chosen for the comparison during cDNA library screening because this region may be less involved in learned fear as opposed to the ventral hippocampus (Bast et al., 2001). We first used two rounds of representation difference analysis (RDA) to enrich the lateral nucleus cDNA probe against the CA1 cDNA sequences. After differential screening of cDNA library derived from single pyramidal amygdala neuron with probes from the lateral nucleus and the CA1 region, we analyzed candidate clones for gene expression pattern using RNA in situ hybridization. We found two genes, *Grp* and *Oncoprotein 18 (Op18)/Stathmin* expressed in the lateral nucleus of the amygdala that had low or no expression in the CA1 region of the hippocampus. Interestingly, these two genes are also expressed in

the accessory basal nucleus (AB) of the amygdala, but are absent in the basal lateral nucleus (BLA) that is located between the lateral nucleus of the amygdala and AB.

5 Both the *Grp* and *Op18/Stathmin* sequences originated from the screening of the same cell, which we identified as glutamatergic pyramidal neuron based on its shape during acute dissociation under the microscope and later by hybridizing its cDNA library  
10 with different neuronal and glial markers and by subsequent characterization of the sequences comprising this cDNA library. This cDNA library (that contained the *Grp* and *Op18/Stathmin* sequences) was positive for neurofilament-L (NF-L, neuronal marker)  
15 and it was negative for glial fibrillary acidic protein (GFAP, glial marker) and glutamic acid decarboxylase (GAD, interneuronal marker). In addition, we isolated from this library a cDNA that corresponds to the zinc transporter-3 (ZnT-3) gene, a  
20 specific marker for zinc-containing subgroup of glutamatergic neurons, highly enriched in the limbic system and the lateral nucleus of the amygdala.

25 *GRP Is Expressed in the Lateral Nucleus of the Amygdala and in the Regions Sending Synaptic Projections to the Lateral Nucleus*

Using in situ hybridization, we next found that the *Grp* gene is highly enriched in the lateral nucleus of the amygdala, and more specifically, in its dorsal and medial subnuclei. In addition, we observed strong  
30 expression in the medial, ventral, and dorsal subdivisions of the medial geniculate body (MGm, MGv, and MGd), the posterior intralaminar nucleus (PIN) of the auditory thalamus, the TE3 subregion of the



auditory cortex, and the perirhinal cortex (PRh, Figure 2B). All of these regions are afferently connected with the lateral nucleus of the amygdala and provide auditory inputs to the lateral nucleus of the amygdala during fear learning (Pitkanen et al., 1997) suggesting that this peptide is involved in auditory cued fear conditioning. For example, MGm and PIN directly project auditory information to the lateral nucleus of the amygdala and to TE3. Area TE3 of the cortex in turn projects to the lateral nucleus of the amygdala (LeDoux, 2000). The ventral subiculum (VS), another structure where the *Grp* is localized, also provides a strong input to the medial division of the lateral nucleus of the amygdala as well as to BLA and AB. PRh is reciprocally connected with the lateral nucleus of the amygdala and is capable of sending either cued or contextual signals. GRP is also expressed in the ventral dentate gyrus. However, a connection between the lateral nucleus of the amygdala or AB and the dentate gyrus is not well documented.

#### *GRPR Is Expressed in Inhibitory Interneurons*

GRP is a peptide neurotransmitter that is selectively recognized by a seven transmembrane domain receptor (GRPR) coupled to Gαq-protein (Hellmich et al., 1999). Having shown that GRP is expressed by principal cells in the lateral nucleus of the amygdala, we were curious to know what types of cells express GRPR. To identify the neurons within the lateral nucleus of the amygdala that express GRPR, we performed colocalization studies using dual fluorescent in situ hybridization for *Grpr* RNA and immunohistochemistry with antibodies against

interneuron-specific marker, glutamic acid  
decarboxylase (GAD67 form, Figure 3A). We found that  
the *Grpr* RNA was expressed selectively in inhibitory  
GABAergic interneurons. However, GRPR was present  
5 only in a subpopulation of GAD-positive interneurons,  
which suggests that the lateral nucleus of the  
amygdala contains various groups of interneurons  
subserving different functions.

Physiological, tract-tracing, and immunocytochemical  
10 studies have shown that afferent signals converging  
onto the lateral nucleus of the amygdala are  
regulated locally in the dorsolateral division by  
inhibitory interneurons (Woodson et al., 2000). The  
afferent glutamatergic projections to the amygdala  
15 synapse on both principal cells and GABAergic  
inhibitory interneurons (Mahanty and Sah, 1998). The  
inhibitory interneurons in turn send feedback  
inhibitory projections to pyramidal neurons. These  
feedback and feedforward GABAergic inputs are thought  
20 to determine how the excitatory inputs to the  
principal cells involved in fear learning are  
processed and conveyed along neural pathways in the  
amygdala (Wang et al., 2001). The observed pattern of  
the *Grp* and *Grpr* genes expression suggested to us  
25 that GRPR exerts a functional role in modulating the  
balance between excitation and inhibition in the  
local neuronal networks related to learned fear (see  
Figure 1).

30 *GRP Appears to Excite GABAergic Inhibitory  
Interneurons in the Lateral Nucleus of the  
Amygdala that Functionally Express GRPR*

To test whether activation of the GRP receptors on  
the GABAergic interneurons in the lateral nucleus of

the amygdala by the release of GRP from principal cells can change the level of tonic inhibition in the principal cell, we carried out whole-cell recordings from visually identified pyramidal neurons in mice.

5 We identified pyramidal neurons based on their appearance and their ability to demonstrate spike frequency adaptation to the prolonged depolarizing current injection (Tsvetkov et al., 2002).

We recorded spontaneous inhibitory postsynaptic

10 currents (sIPSCs) in the pyramidal neurons having blocked the AMPA ( $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor-mediated responses (Figure 2) with CNQX (6-cyano-7-nitroquinoxaline-2,3-dione, 20  $\mu$ M). To increase the inhibitory signals, we

15 inverted the inhibitory currents so that they had an inward direction by dialyzing the postsynaptic cells with a chloride-based intrapipette solution. Consistent with the notion that the sIPSCs are mediated by the GABA<sub>A</sub> receptors, these currents were

20 completely blocked (Figures 2A<sub>3</sub> and 2B<sub>2</sub>) by gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptor antagonist, picrotoxin (50  $\mu$ M,  $n = 10$ ), at a holding potential of -70 mV.

In the absence of a GABA<sub>A</sub> receptor blockade,

25 application of GRP (200 nM) led to a significant increase in the frequency of sIPSCs in the soma of the principal cells of wild-type mice (baseline: 5.23  $\pm$  0.68 Hz; GRP: 10.12  $\pm$  1.0 Hz;  $n = 17$  cells, obtained from 5 control mice; significant difference,

30 paired  $t$  test,  $t = 4.99$ ,  $P < 0.0002$ ; Figures 2A-2C). Therefore, we think that the increase in frequency of GABA sIPSCs was likely due to excitation of the interneurons by GRP leading to an increase in

the firing of action potentials in GABAergic interneurons. We further supported this by blocking the effects of the agonist by applying a Na<sup>+</sup> channel blocker tetrodotoxin (TTX, 1 uM, n = 7; Figure 2A<sub>2</sub>).  
5 These findings in the lateral amygdala are consistent with previous work in the hippocampus, where bombesin-like neuropeptides (including GRP) elicited a marked increase in the frequency of GABA<sub>A</sub> receptor-mediated IPSCs recorded in CA1 pyramidal neurons (Lee  
10 et al., 1999) mediated by depolarization and induced repetitive firing of GABAergic interneurons in the stratum oriens.

We specifically linked the observed effect of the bath-applied GRP to the activation of GRPR. Bath  
15 application of a specific antagonist of GRPR ([D-Phe<sup>6</sup>,Des-Met<sup>14</sup>]-bombesin-(6-14)ethyl amide; 3 uM; Lee et al., 1999) blocked the effect of GRP on the frequency of sIPSCs (Figures 2A, and 2B,; baseline: 5.15 ± 0.91 Hz; GRP: 10.37 ± 1.2 Hz; antagonist of  
20 GRPR: 5.72 ± 1.1 Hz; n = 6 cells). The difference in the frequency of sIPSCs in the baseline conditions and after the GRPR antagonist application was not statistically significant (paired t test, t = 1.21, P = 0.3), suggesting that the bombesin antagonist fully  
25 abolished the GRP-induced increase in the frequency of the sIPSCs.

#### *Knockout of GRPR Eliminates Tonic Inhibition*

To obtain independent evidence that GRP induces enhancement of GABAergic tonic inhibition due to  
30 activation of GRP receptors localized on interneurons, we turned to mice in which the gene for GRPR was knocked out. These mutant mice were

littermates of the control mice we have studied to this point. GRPR knockout mice do not show any obvious developmental anatomical abnormalities throughout their body or their brain (Hampton et al., 1998 and Figure 3B). Immunohistochemistry on brain sections of these mice with interneuron-specific antibodies (pan/albumin, calretinin, and calbindin) revealed no differences between knockout mice and wild-type controls. However, in situ hybridization revealed that the GABAergic interneurons in the knockout mice were lacking GRPR. Consistent with these findings, we found in the mutants that the GRP-mediated negative control of the excitatory synaptic inputs to principal cells in the lateral nucleus was lacking. In slices from mice in which the *Grpr* gene was ablated, bath-applied GRP failed to increase the frequency of sIPSCs (200 nM; baseline:  $5.06 \pm 0.58$  Hz; GRP:  $5.64 \pm 0.67$  Hz;  $n = 23$  cells, obtained from 6 GRPR knockout mice; no significant difference: paired  $t$  test,  $t = 1.04$ ,  $P = 0.31$ ; Figures 4A<sub>3</sub>, 4B<sub>2</sub>, and 4C). These results suggest that GRP receptors are functionally expressed in the lateral nucleus of wild-type mice and that activation of the GRP receptors on these interneurons was responsible for the dramatic increase in the level of tonic GABA inhibition observed in the principal neurons in the lateral nucleus.

*LTP in the Cortico-Amygdala Pathway Is Enhanced in GRPR-Knockout Mice*

Our recent findings indicate that LTP of the synaptic connections in the neural circuit of learned fear is an essential cellular mechanism contributing to the acquisition of memory for fear (Tsvetkov et al. 2002;

see also McKernan and Shinnick-Gallagher, 1997; Rogan et al., 1997). Studies of different brain regions, including the hippocampus (Steele and Mauk, 1999), the cortex (Trepel and Racine, 2000), and the  
5 amygdala (Rammes et al., 2000), indicate that modulation of principal cells by GABA-mediated inhibition can play an important role in the induction of LTP. We therefore asked: does removal of GRPR in the inhibitory interneurons affect LTP in  
10 slices of the lateral nucleus of the amygdala?

We induced LTP of the compound glutamatergic EPSCs at the cortico-amygdala synapses by pairing postsynaptic depolarization from a holding potential of -70 mV to +30 mV with 80 presynaptic stimuli delivered to the  
15 fibers in the external capsule (Huang and Kandel, 1998; Mahanty and Sah, 1998; Weisskopf and LeDoux, 1999) at a frequency of 2 Hz (Figures 3A-3B). We measured LTP with the K-gluconate containing intrapipette solution, without picrotoxin in the bath  
20 (see Experimental Procedures). Under these experimental conditions, the peak amplitude of the evoked EPSC was solely determined by activation of the AMPA glutamate receptors. The contribution of the GABA<sub>A</sub> receptor-mediated component to the EPSC was  
25 negligible at such holding potential since it was very close to the reversal potential ( $E_r$ ) of GABA<sub>A</sub> IPSC ( $-67 \pm 3$  mV,  $n = 6$ ; Figure 3C). This induction protocol was used because, as we have shown previously, it consistently produces robust LTP  
30 (Tsvetkov et al., 2002). We have deliberately chosen to depolarize a postsynaptic cell to a more positive membrane potential during the induction period, than in some previous studies, to allow a maximal

activation of L-type  $\text{Ca}^{2+}$  channels (e.g., Mermelstein et al., 2000), as they were shown to take part in the induction process (Tsvetkov et al., 2002; Weisskopf et al., 1999). Keeping  $\text{Ca}^{2+}$  influx through L-type  $\text{Ca}^{2+}$  channels at a relatively constant level, we minimize a possible non-linearity of the interaction between the NMDA receptor and  $\text{Ca}^{2+}$  channel-mediated contribution to the integral postsynaptic calcium signal, thus maintaining the more uniform induction conditions. When LTP at the cortical input to the amygdala was compared (in a blinded fashion) in slices from control and from GRPR knockout mice, we found that LTP was significantly greater in knockout than in control mice (Figure 3B), with an average LTP of the EPSC to  $2.02 \pm 0.2$  ( $n = 12$  cells) and  $1.33 \pm 0.13$  ( $n = 9$  cells) of the baseline EPSC value, respectively. The difference in the amount of LTP measured over a 5 min period (between 35 and 40 min after pairing) between control and knockout mice was statistically significant (t-test,  $t = 2.96$ ,  $P < 0.01$ ). Thus, the ablation of the *Grpr* gene disinhibits the pyramidal cells and makes the cortico-amygdala synapses more susceptible to LTP. To obtain independent support for this conclusion, we measured the pairing-induced LTP in slices from wild-type mice in the presence of the bombesin antagonist. Under these conditions, LTP also was significantly enhanced (Figure 5D, control LTP:  $1.42 \pm 0.04$ ,  $n = 5$  cells; LTP with the antagonist:  $1.92 \pm 0.05$ ,  $n = 7$  cells; significant difference, t test,  $t = 8.1$ ,  $P < 0.0001$ ).

*GRPR-Deficient Mice Have Enhanced and Persistent  
Long-Term Memory for Fear to Both Auditory and  
Contextual Cues*

We first trained GRPR-deficient mice in Pavlovian  
5 cued and contextual fear conditioning, an amygdala-  
dependent task, which depends on the ability of the  
animal to learn and remember that auditory cue or  
context predict electric shock. During training, the  
level of overall freezing of knockout animals was not  
10 significantly different from wild-type littermate  
controls. For both groups, freezing was slightly  
increased within 30 s immediately after training  
(Figure 4A). When tested for amygdala-dependent tone  
fear conditioning, mice were placed in a new context  
15 24 hr after training (Figure 4A<sub>2</sub>). Mice displayed an  
increase in freezing at the onset of the tone (CS;  
cued fear conditioning) as compared to the freezing  
prior (pre-CS) to the tone (Session effect, all  $p < 0.01$ ). In addition, the ANOVA revealed a significant  
20 effect of genotype showing that GRPR knockout mice  
froze more than the wild-type mice at the  
presentation of the tone which had been associated  
previously with the electric shock (genotype effect:  
[ $F(1,16) = 13.30$ ;  $p = 0.002$ ]). Although freezing de-  
25 creased with time in both groups of mice (Session  
effect; all  $p < 0.01$ ), GRPR knockout mice produced a  
higher response to the tone in subsequent CS cued-  
testing sessions at 2, 7, and 15 weeks (Genotype  
effect; all  $p < 0.05$ ).

30 Contextual fear conditioning is dependent both on the  
amygdala and the hippocampus. Here, mice were tested  
in the absence of cue in the same context 24 hr after  
training. Both mutant and wild-type mice exhibited  
higher level of freezing compared to immediately



after the shock (Session effect, all  $p < 0.0001$ , Figure 4A). This suggests that the mutant mice not only remembered the context where they received the shock the day before, but that they also developed  
5 with time a strong aversive response to this environment associated with a painful experience. The ANOVA revealed a significant effect of genotype ( $[F(1,16) = 25.07; p = 0.0001]$ ) showing that both groups of mice froze differently in this context,  
10 with GRPR knockout mice showing a higher response as compared to their control littermates. Although freezing to context decreased in both groups of mice with time (Session effect, all  $p < 0.0001$ ) suggesting similar rate of extinction, the observed increase in  
15 freezing in GRPR knockout mice was still present in subsequent testing sessions at 2, 7, and 15 weeks (Genotype effect, all  $p < 0.05$ ).

We also analyzed mutant mice for short-term memory at 30 min and at 4 hr in independent groups. For both  
20 time points, there was no significant difference between mutant and wild-type mice in both contextual and cued fear conditioning (Figure 4B). Thus, the enhancement in learned fear observed in GRPR knockout mice is specific to long-term but not short-term  
25 memory.

To verify that the increase in freezing displayed by GRPR knockout mice in the fear conditioning experiment was not due to an increased sensitivity to the shock, we performed a control experiment in which  
30 we administered electric shock of increasing intensity while recording the behavioral response exhibited by the mice (Harrel, 2001). There was no difference between groups in the intensity of shock

required to elicit movement, vocalization, or jump  
(Figure 2D), indicating that an increase in freezing  
observed in the fear conditioning experiments was due  
to the learning process and not to a difference in  
5 pain sensitivity.

*The Enhanced and Persistent Fear Is Learned and  
Not Secondary to Chronic Anxiety*

To explore further these mice's tendency for innate  
(not learned) fear, we used the elevated plus maze  
10 where mice face a conflict between an innate aversion  
to the open arms of the maze and the motivation to  
explore this compartment (Ramboz et al., 1998). The  
ANOVA conducted on the number of entries in the open  
and closed arms and on the index of anxiety (time  
15 spent/ entries in the open arms) did not reveal any  
significant effect of genotype (Figure 4E). Thus, in  
the elevated plus maze, the basal level of anxiety  
was similar in control and GRPR knockout mice.

Another way to assess anxiety in mice is a light-dark  
20 box test (Johansson et al., 2001). In this test, mice  
tend to avoid the light compartment and naturally  
prefer the dark one. Here again, we did not find any  
difference between groups in the number of entries as  
well as the total time spent in the lit compartment.  
25 Thus, as with the elevated plus maze, the results  
from the light-dark box test suggest that the basal  
level of anxiety in GRPR knockout mice is similar to  
that of wild-type mice.

*The GRPR Knockout Mice Show Normal Hippocampus-  
Dependent Spatial Memory*

Because GRP is expressed in the lateral nucleus of  
the amygdala and specifically in its circuitry for

learned fear and we have found that knockout of GRPR enhances amygdala-based learning, we were curious to know if we can use GRPR-deficient mice to dissociate amygdala-dependent from hippocampus-dependent learning. To determine whether GRPR is important for a purely hippocampus-based task, we turned to the Morris water maze, a task in which the amygdala is not involved. In this maze, an animal has to remember the position of a hidden escape platform in relationship to distal cues surrounding it in a circular pool (Malleret et al., 1999). During acquisition of the Morris water maze, mice from all groups showed a decrease in escape latency (Figure 4C<sub>1</sub>) across days, indicating learning of the platform position (all groups,  $p < 0.0001$ ). They also showed a preference for the target quadrant during the probe trial performed on the last day of the experiment (Figure 4C<sub>4</sub>). We found no differences between groups in this task (no genotype effect), suggesting that the deletion of the GRPR does not enhance hippocampus-dependent learning that is independent of the amygdala, which is similar to the results of Wada and coworkers (Wada et al., 1997). These results support the notion that the amygdala is directly involved in learned fear (Fanselow and LeDoux, 1999) and that it does not merely modulate memories formed in other brain structures like the hippocampus.

### Discussion

We have identified, characterized, and localized to a specific inhibitory neural circuit in the lateral nucleus of the amygdala a molecular signaling network important for learned fear. When this inhibitory molecular network is disrupted, mice show

increased LTP in the lateral nucleus of the amygdala and an enhanced memory of learned fear as evident in both cued and contextual fear conditioning. There is a normal memory for hippocampus-based spatial task  
5 indicating that this network is specifically involved in the regulation of memory formation in the amygdala in response to danger signals. There also is no alteration in innate fear.

Experiments in humans and in experimental animals  
10 over the last half a century indicate that the amygdala is involved in learned fear (Davis and Whalen, 2001; LeDoux, 2000). In the past 50 years, we have learned a fair amount about the anatomy and cell physiology underlying amygdala-based fear. For  
15 example, recent experiments have demonstrated that the mechanisms of LTP are recruited behaviorally at the synapses in the lateral nucleus of the amygdala during training for learned fear (Rogan et al., 1997; McKernan and Shinnick-Gallagher, 1997; Tsvetkov et  
20 al., 2002), thus providing direct support for the link between LTP and memory storage. By contrast, very little is known about the molecular mechanisms contributing to this form of fear. This is unfortunate because the neuronal pathways carrying  
25 sensory information for unimodal learned fear (the information carried by the CS) is much better specified than that for the sensory information for spatial learning as is the correlation between LTP and memory storage.

30 We therefore have isolated amygdala-enriched genes and then, using mouse genetics in combination with physiological and behavioral approaches studied the role of these genes in the memory for fear.

Initially, we isolated two genes expressed in a glutamatergic principal neuron of the lateral nucleus of the amygdala. The first of these genes, *Op18/Stathmin*, is highly expressed both in the lateral nucleus of the amygdala and in the cerebral cortex with very little expression in the hippocampus. *Op18/Stathmin* is a phosphoprotein that binds tubulin dimers and destabilizes cellular microtubules (Belmont and Mitchison, 1996). It is a major substrate for protein kinase A and upon phosphorylation releases tubulin thus allowing polymerization of tubulin molecules. *Op18/Stathmin* mRNA levels are increased after lesions to the perforant pathway of the hippocampus, which together with the biochemical role of *Op18/Stathmin* protein suggests its involvement in synaptogenesis (Brauer et al., 2001).

The second gene, *Grp*, is uniquely localized in the lateral and accessory basal nuclei of the amygdala and in regions that send projections to it and which are essential for delivering information about CS to the amygdala during Pavlovian fear conditioning (LeDoux, 2000). In particular, our analysis showed that the *Grp* gene is expressed both in the areas specific to pathways delivering tone CS information and in the areas specific to pathways delivering contextual CS information. GRP is a 29 amino acid long mammalian homolog of the amphibian peptide bombesin (Kroog et al., 1995) and may serve as a cotransmitter with glutamate in pyramidal neurons in the rodent brain (Lee et al., 1999 and our present data). Our observation of the *Grp* gene expression pattern specific to the fear network of the amygdala

finds support in the report that GRP concentration was increased in the central nucleus of the rat amygdala during both stress and feeding (Merali et al., 1998). GRPR is a G<sub>i</sub>q protein-coupled receptor and its downstream targets include protein kinase C (PKC- $\beta$ ) and phospholipase C as shown both in cultured mouse fibroblasts and rat hippocampal neurons (Mellmich et al., 1999; Lee et al., 1999). GRPR activation by GRP binding leads to intracellular release of Ca<sup>2+</sup> and eventually to the activation of the MAPK pathway (Sharif et al., 1997).

We found that GRP is expressed in a group of glutamatergic principal neurons enriched in zinc. Interestingly, zinc-containing glutamatergic neurons constitute a specific network circuitry that includes the lateral nucleus of the amygdala and other components of the limbic system (reviewed in Frederickson et al., 2000). We next found, as did Lee and colleagues (1999), that GRPR is expressed in GABAergic interneurons. We also found that GRPR activation can significantly enhance the level of tonic GABA-mediated inhibition in the lateral nucleus. Recent pharmacological and genetic studies have shown that the establishment of a balance between glutamatergic excitatory and GABAergic inhibitory functions is critical for processing of information in the amygdala (Bast et al., 2001; Krezel et al., 2001). Based on these published data and our results, we suggest a model of GRP action in the amygdala during fear response; during excitation, the glutamatergic principal cells may release as a cotransmitter the excitatory peptide, GRP. Through the binding to GRPR on interneurons, GRP leads to

GABA release. This may provide tonic, feedforward, or feedback inhibitory control of the processing of CS stimuli by principal cells (Figure 7, left image). Thus, this molecular signaling pathway provides a control which can regulate the balance between excitatory and inhibitory circuitries in the amygdala.

*GRPR-Deficient Mice Show Both Enhanced LTP and Enhanced Memory Storage in Amygdala-Dependent Tasks*

10 To test this model, we next examined the pyramidal neurons in the lateral nucleus of the amygdala of GRPR knockout animals and found that indeed they lack an inhibitory control normally provided by GRP in wild-type conditions (Figure 7, right image). As a result of lacking inhibition, there is an enhanced LTP in the cortico-amygdala pathway. In agreement with our genetic finding, previous pharmacological work has demonstrated that modulation of the level of GABA-mediated inhibition of the principal cells in the amygdala may determine how easily LTP is induced at the amygdala synapses (Krezel et al., 2001; Rammes et al., 2000).

Consistent with an enhancement of LTP, these animals also show enhanced freezing in both cued and contextual versions of amygdala-dependent fear conditioning task. Throughout all time points tested (the latest 15 weeks after training), mutant mice had higher freezing than normal mice. This may be due to faster fear memory retrieval in mutant mice because during testing mutants started freezing right after the tone was turned on but wild-types froze a few seconds later. The fading over time of the phenotype of GRPR knockout mice for fear conditioning might

reflect the contribution of shock-induced sensitization in addition to the enhancement in learning. In contrast to long-term effects, we found that mutant mice have normal short-term memory when  
5 tested at 30 min and even 4 hr after training. This finding suggests the interesting possibility that GRP/GRPR signaling pathway modulates learned fear in a long-term specific manner and thus provides further support to the notion that LTP is implicated in the  
10 mechanisms of long-term memory. Importantly, GRPR-deficient mice showed normal memory in the Morris water maze, which is dependent on the hippocampus but not the amygdala. This finding is again consistent with fear circuitry-specific expression pattern of  
15 the *Grp* gene and allowed us to dissociate amygdala-based behavior from hippocampus-based behavior. Thus, we identified a network that is specifically involved in amygdala-dependent long-term memories for fear.

#### 20        *A Possible Role of GRP Pathway in Mental Disorders*

The analysis of mice with decreased GABA function may have important clinical implications. Decreased levels of GABA have consistently been found in patients with depression, panic, and generalized  
25 anxiety disorders (Goddard et al., 2001) and some of the drugs currently used to treat panic and generalized anxiety disorders increase levels of GABA in the brain (Parent et al., 2002). We did not find any abnormalities in basal or in innate anxiety of  
30 GRPR knockout mice probably because we did not disrupt directly the biochemical machinery involved in GABA production and utilization. Rather, we interfered with the GABA functions by disrupting a



network that regulates GABA release. The reduction in GABA release in mutant mice seems to fine-tune the memory storage system so as to improve memory storage for fear. Perhaps, greater depleting GABA would lead to the opposite effects; it might decrease memory storage for fear and lead to high levels of anxiety similar to that described in mice mutant for GABA receptors (Low et al., 2000; McKernan et al., 2000). Since of all mental disorders anxiety disorders are those that can best be modeled in mice and other experimental animals (Bachevalier et al., 2001), it is likely that molecular insights in the biology of fear will prove to be broadly informative regarding the genes important both for normal human fear and for anxiety states.

Indeed, recent studies have suggested the possible involvement of GRP and GRPR in mental disorders. *GRPR* is a candidate gene for autism; an X;8 translocation has been found that disrupted the first intron of the *GRPR* gene in an autistic female patient (Ishikawa-Brush et al., 1997). Importantly, genetic studies in autistic patients have pinpointed chromosomal abnormalities in the 15q11-q13, a region where the *GABRB3* gene is located, which codes for the beta 3 subunit of the gamma-amino-butyric acid (GABA)<sub>A</sub> receptor (Cook et al., 1998). Moreover, recent behavioral, anatomical, and neuroimaging studies suggest that one of the critical loci for autism resides in the amygdala (Baron-Cohen et al., 2000).

Taken altogether, these observations demonstrate the importance of determining molecular substrates of a

mygdala-dependent memory processes and identify the components of GRP/GRPR molecular network as a clear target for treating anxiety disorders.

## References

- Bachevalier, J. et al. (2001). Effects of selective neonatal temporal lobe lesions on socioemotional behavior in infant rhesus monkeys (*Macaca mulatta*).  
5 Behav. Neurosci. 775, 545-559.
- Baron-Cohen, S. et al. (2000). The amygdala theory of autism. *Neurosci. Biobehav. Rev.* 24, 355-364.
- Bast, T. et al. (2001). The ventral hippocampus and fear conditioning in rats. Different anterograde  
10 amnesias of fear after tetrodotoxin inactivation and infusion of the GABA(A) agonist muscimol. *Exp. Brain Res.* 739, 39-52.
- Belmont, L.D., and Mitchison, T.J. (1996). Identification of a protein that interacts with  
15 tubulin dimers and increases the catastrophe rate of microtubules. *Cell* 84, 623-631.
- Bolshakov, V.Y. et al. (1997). Recruitment of new sites of synaptic transmission during the cAMP-dependent late phase of LTP at CA3-CA1 synapses in  
20 the hippocampus. *Neuron* 79, 635-651.
- Bolshakov, V.Y. et al. (2000). Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3-CA1 synapses. *Nat. Neurosci.* 3,1107-1112.
- 25 Bourtchouladze, R. et al. (1998). Different training procedures recruit either one or two critical periods for contextual memory consolidation, each of which requires protein synthesis and PKA. *Learn. Mem.* 5, 365-374.

- Brauer, A.U. et al. (2001). Perforant path lesion induces up-regulation of stathmin messenger RNA, but not SCG10 messenger RNA, in the adult rat hippocampus. *Neuroscience* 702, 515-526.
- 5 Cook, E.H. et al. (1998). Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. *Am. J. Hum. Genet.* 62,1077-1083.
- Darker JG et al. (2001). Discovery of potent and selective peptide agonists at the GRP-preferring  
10 bombesin receptor (BB2). *J.Pept.Sci.* 7(11):598-605.
- Davis, M., and Whalen, PJ. (2001). The amygdala: vigilance and emotion. *Mol. Psychiatry* 6,13-34.
- Dulac, C., and Axel, R. (1995). A novel family of genes encoding putative pheromone receptors in  
15 mammals. *Cell* 83,195-206.
- Fanselow, M.S., and LeDoux, J.E. (1999). Why we think plasticity underlying Pavlovian fear conditioning occurs in the basolateral amygdala. *Neuron* 23, 229-232.
- 20 Frederickson, C.J. et al. (2000). Importance of zinc in the central nervous system: the zinc-containing neuron. *J. Nutr.* 730,1471S-1483S.
- Goddard, A.W. et al. (2001). Reductions in occipital cortex GABA levels in panic disorder detected with  
25 1h-magnetic resonance spectroscopy. *Arch. Gen. Psychiatry* 58, 556-561.
- Hampton, L.L. et al. (1998). Loss of bombesin-induced feeding suppression in gas-trin-releasing peptide receptor-deficient mice. *Proc. Natl. Acad. Sci. USA*

95, 3188-3192.

Harrel, A.V. et al. (2001). Transgenic mice over-expressing the 5-HT<sub>3</sub> receptor have enhanced learning in latent inhibition and contextual fear conditioning paradigms. Paper presented at Abstracts, Society for Neuroscience, 31st Annual Meeting, San Diego, California.

Hellmich, M.R. (1999). Multiple protein kinase pathways are involved in gastrin-releasing peptide receptor-regulated secretion. J. Biol. Chem. 274, 23901-23909.

Huang, Y.Y., and Kandel, E.R. (1998). Postsynaptic induction and PKA-dependent expression of LTP in the lateral amygdala. Neuron 27,169-178.

Hubank, M., and Schatz, D.G. (1994). Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res. 22, 5640-5648.

Ishikawa-Brush, Y. et al. (1997). Autism and multiple exostoses associated with an X;8 translocation occurring within the GRPR gene and 3' to the SDC2 gene. Hum. Mol. Genet. 6,1241-1250.

Johansson, B. et al. (2001). Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A<sub>1</sub> receptor. Proc. Natl. Acad. Sci. USA 98, 9407-9412.

Kapp, B.S. et al. (1992). Amygdaloid contributions to conditioned arousal and sensory information processing. In The Amygdala: Neurobiological Aspects of Emotion, Memory, and Mental Dysfunction, J.P.

- Aggleton, ed. (New York: Wiley-Liss), pp. 229-254.
- Krezel, W. et al. (2001). Increased anxiety and synaptic plasticity in estrogen receptor p-deficient mice. *Proc. Natl. Acad. Sci. USA* 98,12278-12282.
- 5 Kroog, G.S. et al. (1995). Mammalian bombesin receptors. *Med. Res. Rev.* 75, 389-417.
- LeDoux, J.E. (2000). Emotion circuits in the brain. *Annu. Rev. Neurosci.* 23, 155-184.
- Lee, K. et al. (1999). Bombesin-like peptides  
10 depolarize rat hippocampal interneurons through interaction with subtype 2 bombesin receptors. *J. Physiol.* 578, 791-802.
- Low, K. et al. (2000). Molecular and neuronal substrate for the selective attenuation of anxiety.  
15 *Science* 290,131-134.
- Mahanty, N.K., and Sah, P. (1998). Calcium-permeable AMPA receptors mediate long-term potentiation in interneurons in the amygdala. *Nature* 394, 683-687.
- Malleret, G. et al. (1999). 5-HT1B receptor knock-out  
20 mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze. *J. Neurosci.* 79, 6157-6168.
- McKernan, M.G., and Shinnick-Gallagher, P. (1997). Fear conditioning induces a lasting potentiation of  
25 synaptic currents in vitro. *Nature* 390, 607-611.
- McKernan, R.M. et al. (2000). Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha subtype. *Nat. Neurosci.*

3, 587-592.

Merali, Z. et al. (1998). Aversive and appetitive events evoke the release of corticotropin-releasing hormone and bombesin-like peptides at the central  
5 nucleus of the amygdala. *J. Neurosci.* 78, 4758-4766.

Mermelstein, P.G., et al. (2000). Critical dependence of cAMP response element-binding protein phosphorylation on L-type calcium channels supports a selective response to EPSPs in preference to action  
10 potentials. *J. Neurosci.* 20, 266-273.

Parent, M.B. et al. (2002). Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the  
15 striatum. *Biochem. Pharmacol.* 63, 57-64.

Pitkanen, A. et al. (1997). Organization of intra-amygdaloid circuitries in the rat: an emerging framework for understanding functions of the amygdala. *Trends Neurosci.* 20, 517-523.

20 Ramboz, S. et al. (1998). Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. *Proc. Natl. Acad. Sci. USA* 95, 14476-14481.

Rammes, G. et al. (2000). Synaptic plasticity in the basolateral amygdala in transgenic mice expressing  
25 dominant-negative cAMP response element-binding protein (CREB) in forebrain. *Eur. J. Neurosci.* 72, 2534-2546.

Rogan, M.T. et al. (1997). Fear conditioning induces associative long-term potentiation in the amygdala.

Nature 390, 604-607.

Romanski, L.M., and LeDoux, J.E. (1992). Equipotentiality of thalamoamygdala and thalamocortico-amygdala circuits in auditory fear  
5 conditioning. J. Neurosci. 72, 4501-4509.

Schaeren-Wiemers, N., and Gerfin-Moser, A. (1993). A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: in situ hybridization using  
10 digoxigenin-labeled cRNA probes. Histochemistry 700, 431-440.

Sharif, T.R. et al. (1997). Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines; role in mitogenesis and in  
15 stimulating the mitogen-activated protein kinase pathway. Mol. Cell. Endocrinol. 130, 119-130.

Steele, P.M., and Mauk, M.D. (1999). Inhibitory control of LTP and LTD: stability of synapse strength. J. Neurophysiol. 81, 1559-1566.

20 Trepel, C., and Racine, R.J. (2000). GABAergic modulation of neocortical long-term potentiation in the freely moving rat. Synapse 35, 120-128.

Tsvetkov, E. et al. (2002). Fear conditioning occludes LTP-induced presynaptic enhancement of  
25 synaptic transmission in the cortical pathway to the lateral amygdala. Neuron 34, 289-300.

Wada, E. et al. (1997). Generation and characterization of mice lacking gastrin-releasing peptide receptor. Biochem. Biophys. Res. Commun. 239,



28-33.

Wang, C. et al. (2001). Role of NMDA, non-NMDA, and GABA receptors in signal propagation in the amygdala formation. *J. Neurophysiol.* 86, 1422-1429.

- 5 Weisskopf, M.G., and LeDoux, J.E. (1999). Distinct populations of NMDA receptors at subcortical and cortical inputs to principal cells of the lateral amygdala. *J. Neurophysiol.* 81, 930-934.

Weisskopf, M.G. et al. (1999). L-type voltage-gated  
10 calcium channels mediate NMDA-independent associative long-term potentiation at thalamic input synapses to the amygdala. *J. Neurosci.* 79, 10512-10519.

Woodson, W. et al. (2000). Afferents from the auditory thalamus synapse on inhibitory interneurons  
15 in the lateral nucleus of the amygdala. *Synapse* 38, 124-137.

Yu, B., and Shinnick-Gallagher, P. (1997). Dihydropyridine- and neurotoxin-sensitive and insensitive calcium currents in acutely dissociated  
20 neurons of the rat central amygdala. *J. Neurophysiol.* 77, 690-701.

What is claimed is:

1. A method for treating a subject afflicted with a fear-related disorder comprising administering to the subject a therapeutically effective amount of a gastrin-releasing peptide receptor agonist.  
5
2. The method of claim 1, wherein the subject is human.  
10
3. The method of claim 1, wherein the fear-related disorder is a phobia.
4. The method of claim 1, wherein the fear-related disorder is chronic anxiety.  
15
5. The method of claim 1, wherein the fear-related disorder is a panic attack.
- 20 6. The method of claim 1, wherein the fear-related disorder is post-traumatic stress disorder.
7. The method of claim 1, wherein the fear-related disorder is autism.  
25
8. A method for inhibiting in a subject the onset of a fear-related disorder resulting from exposure to a traumatic experience comprising administering a prophylactically effective amount of a gastrin-releasing peptide receptor agonist to the subject prior to and/or following the traumatic experience.  
30

9. The method of claim 8, wherein the subject is human.
- 5 10. The method of claim 8, wherein the fear-related disorder is a phobia.
11. The method of claim 8, wherein the fear-related disorder is chronic anxiety.
- 10 12. The method of claim 8, wherein the fear-related disorder is a panic attack.
- 15 13. The method of claim 8, wherein the fear-related disorder is post-traumatic stress disorder.
- 20 14. The method of claim 8, wherein the agonist is administered to the subject prior to the traumatic experience.
- 25 15. The method of claim 14, wherein the traumatic experience is military combat.
- 30 16. The method of claim 8, wherein the agonist is administered to the subject after the traumatic experience.
17. The method of claim 16, wherein the traumatic experience is a physical assault.
18. An article of manufacture comprising (a) a packaging material having therein a gastrin-releasing peptide receptor agonist, and (b) a

label indicating a use for the agonist in treating, and/or inhibiting the onset of, a fear-related disorder in a subject.

- 5        19. A nucleic acid comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-releasing peptide.
- 10
20. A bacterial artificial chromosome (BAC) comprising the nucleic acid of claim 20.
- 15        21. A transgenic animal whose somatic cells have stably integrated therein a nucleic acid comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-releasing peptide, and wherein the polypeptide is specifically expressed in the animal's amygdala.
- 20
22. The transgenic animal of claim 22, wherein the animal is a mouse.
- 25
23. A method for producing a transgenic animal whose amygdaloid cells specifically express an exogenous polypeptide, which method comprises producing a transgenic animal by introducing into an oocyte an exogenous DNA so that the exogenous DNA is stably integrated into the oocyte, and permitting the resulting oocyte to mature into a viable
- 30

animal, wherein (a) the animal's somatic  
cells have the exogenous DNA stably  
integrated therein, (b) the exogenous DNA  
comprises a gastrin-releasing peptide gene,  
5 wherein the gene has inserted into it, either  
at its start or stop codon, an exogenous  
polypeptide-encoding sequence, and the  
exogenous polypeptide is not gastrin-  
releasing peptide, and (c) the exogenous  
10 polypeptide is specifically expressed in the  
animal's amygdala.


24. The method of claim 23, wherein the animal is  
a mouse.

15


GRP RECEPTOR-RELATED METHODS FOR TREATING AND  
PREVENTING FEAR-RELATED DISORDERS

Abstract of the Disclosure

This invention provides a method for treating a  
5 subject afflicted with a fear-related disorder  
comprising administering to the subject a  
therapeutically effective amount of a gastrin-  
releasing peptide receptor agonist. This invention  
further provides a method for inhibiting in a subject  
10 the onset of a fear-related disorder resulting from  
exposure to a traumatic experience comprising  
administering a prophylactically effective amount of  
a gastrin-releasing peptide receptor agonist to the  
subject prior to and/or following the traumatic  
15 experience. This invention further provides related  
articles of manufacture, and related nucleic acids  
and transgenic animals.




**FIGURE 1**




**FIGURE 2**







**FIGURE 3**



**FIGURE 4 A-B**



**FIGURE 4 C-E**



**FIGURE 5**